Trump’s drug plan could lower total spending, but increase patient costs, study finds

(By Morgan Haefner for Becker’s Hospital Review)

While a new proposal from the Trump administration may lead to reductions in overall prescription drug spending, some Medicare beneficiaries could see their out-of-pocket costs increase, according to a study published in JAMA Internal Medicine.

Five things to know:  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.